AP 30663

Drug Profile

AP 30663

Alternative Names: AP30663-

Latest Information Update: 05 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NeuroSearch
  • Developer Acesion Pharma
  • Class Indoles; Oximes; Small molecules
  • Mechanism of Action Intermediate conductance calcium activated potassium channel modulators; Small conductance calcium activated potassium channel modulators; Small conductance calcium-activated potassium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Atrial fibrillation

Most Recent Events

  • 02 Feb 2018 Phase-I clinical trials in Atrial fibrillation in Denmark (PO) (NTR7012)
  • 15 Dec 2011 Preclinical trials in Atrial fibrillation in Denmark (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top